In recent years, potent but transient inhibition of BCR-ABL kinase in CML, and PI3K in breast cancer models has been shown to be an effective therapeutic strategy [20, 21, 22]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.